Abstract:Background: Atherosclerosis is a chronic inflammatory disorder whose development is inversely correlated with high-density lipoprotein concentration. Current therapies involve pharmaceuticals that significantly elevate plasma high-density lipoprotein cholesterol concentrations. Our studies were conducted to investigate the effects of low-dose lipid-free apolipoprotein A-I (apoA-I) on chronic inflammation. The aims of these studies were to determine how subcutaneously injected lipid-free apoA-I reduces accumulation of lipid and immune cells within the aortic root of hypercholesterolemic mice without sustained elevations in plasma high-density lipoprotein cholesterol concentrations. Methods and results: Ldlr-/- and Ldlr-/- apoA-I-/- mice were fed a Western diet for a total of 12 weeks. After 6 weeks, a subset of mice from each group received subcutaneous injections of 200 μg of lipid-free human apoA-I 3 times a week, while the other subset received 200 μg of albumin, as a control. Mice treated with lipid-free apoA-I showed a decrease in cholesterol deposition and immune cell retention in the aortic root compared with albumin-treated mice, regardless of genotype. This reduction in atherosclerosis appeared to be directly related to a decrease in the number of CD131 expressing cells and the esterified cholesterol to total cholesterol content in several immune cell compartments. In addition, apoA-I treatment altered microdomain cholesterol composition that shifted CD131, the common β subunit of the interleukin 3 receptor, from lipid raft to nonraft fractions of the plasma membrane. Conclusions: ApoA-I treatment reduced lipid and immune cell accumulation within the aortic root by systemically reducing microdomain cholesterol content in immune cells. These data suggest that lipid-free apoA-I mediates beneficial effects through attenuation of immune cell lipid raft cholesterol content, which affects numerous types of signal transduction pathways that rely on microdomain integrity for assembly and activation.

Amino acid starvation‐induced LDLR trafficking accelerates lipoprotein endocytosis and LDL clearance

Ascorbic Acid Enhances Low-Density Lipoprotein Receptor Expression by Suppressing Proprotein Convertase Subtilisin/kexin 9 Expression.

Native and Oxidized Low-Density Lipoproteins Increase the Expression of the LDL Receptor and the LOX-1 Receptor, Respectively, in Arterial Endothelial Cells

Minimally modified low-density lipoprotein induces macrophage endoplasmic reticulum stress via toll-like receptor 4.

Low Density Lipoprotein Mimics Insulin Action on Autophagy and Glucose Uptake in Endothelial Cells

Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio

Lipid droplet-associated hydrolase mobilizes stores of liver X receptor sterol ligands and protects against atherosclerosis

Scavenger receptor a mediates glycated LDL transcytosis across endothelial cells to promote atherosclerosis

Lipopolysaccharide binding protein resists hepatic oxidative stress by regulating lipid droplet homeostasis

Low density lipoprotein induces eNOS translocation to membrane caveolae: the role of RhoA activation and stress fiber formation.

Possible non-classic intracellular and molecular mechanisms of LDL cholesterol action contributing to the development and progression of atherosclerosis

Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding scavenger receptor B1

LncRNA AC096664.3/PPAR‐γ/ABCG1‐dependent Signal Transduction Pathway Contributes to the Regulation of Cholesterol Homeostasis

Native LDL Upregulation of ATP-Binding Cassette Transporter-1 in Human Vascular Endothelial Cells

Impaired lipophagy in endothelial cells with prolonged exposure to oxidized low‐density lipoprotein

Direct effects of adipocyte lipolysis on AMPK through intracellular long-chain acyl-CoA signaling

Huanglian Jiedu Decoction enhances the stability of atherosclerotic plaques through SLC2A1-mediated efferocytosis

Feedback Regulation of Coronary Artery Disease Susceptibility Gene ADTRP and LDL Receptors LDLR/CD36/LOX-1 in Endothelia Cell Functions Involved in Atherosclerosis

LDL induces transcription factor activator protein-1 in human endothelial cells.

Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids

Glucagon-like Peptide-1 Receptor Agonist Dulaglutide Prevents Ox-Ldl-induced Adhesion of Monocytes to Human Endothelial Cells: an Implication in the Treatment of Atherosclerosis.